{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T10:39:28Z","timestamp":1775039968182,"version":"3.50.1"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.coi.2025.102673","type":"journal-article","created":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T01:40:47Z","timestamp":1759628447000},"page":"102673","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["When granulomatous inflammation becomes visible: insights into cutaneous sarcoidosis"],"prefix":"10.1016","volume":"97","author":[{"given":"Mariam","family":"Alam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avrom S.","family":"Caplan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Misha","family":"Rosenbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2025.102673_bib1","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1055\/s-0040-1713130","article-title":"Cutaneous sarcoidosis","volume":"41","author":"Caplan","year":"2020","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.coi.2025.102673_bib2","first-page":"268","article-title":"Granulomatous cutaneous sarcoidosis: diagnosis, relationship to systemic disease, prognosis and treatment","volume":"30","author":"Ma\u00f1\u00e1","year":"2013","journal-title":"Sarcoidosis Vasc Diffuse\u00a0Lung Dis"},{"key":"10.1016\/j.coi.2025.102673_bib3","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s40257-022-00693-0","article-title":"The evolving landscape of cutaneous sarcoidosis: pathogenic insight, clinical challenges, and new frontiers in therapy","volume":"23","author":"Wu","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.coi.2025.102673_bib4","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1111\/jdv.13760","article-title":"Epidemiology of cutaneous sarcoidosis, 1976\u20132013: a population-based study from Olmsted County, Minnesota","volume":"30","author":"Ungprasert","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.coi.2025.102673_bib5","series-title":"Interdisciplinary Approaches to Overlap Disorders in Dermatology and Rheumatology","first-page":"199","article-title":"Sarcoidosis","author":"Rosenbach","year":"2022"},{"key":"10.1016\/j.coi.2025.102673_sbref6","doi-asserted-by":"crossref","DOI":"10.1016\/j.xjidi.2023.100220","article-title":"Molecularly targeted therapies for inflammatory cutaneous granulomatous disorders: a review of the evidence and implications for understanding disease pathogenesis","volume":"3","author":"Hwang","year":"2023","journal-title":"JID Innov"},{"key":"10.1016\/j.coi.2025.102673_bib7","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1055\/s-0037-1602380","article-title":"L\u00f6fgren\u2019s syndrome: diagnosis, management, and disease pathogenesis","volume":"38","author":"Karakaya","year":"2017","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.coi.2025.102673_bib8","first-page":"719.e1","article-title":"Sarcoidosis: a comprehensive review and update for the dermatologist: Part II. Extracutaneous disease","volume":"66","author":"Haimovic","year":"2012","journal-title":"J\u00a0Am\u00a0Acad\u00a0Dermatol"},{"key":"10.1016\/j.coi.2025.102673_bib9","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.chest.2017.10.014","article-title":"Clinical course of sarcoidosis in World Trade Center-exposed firefighters","volume":"153","author":"Hena","year":"2018","journal-title":"Chest"},{"key":"10.1016\/j.coi.2025.102673_bib10","first-page":"482","article-title":"Cutaneous sarcoidosis","volume":"23","author":"Noe","year":"2017","journal-title":"Curr\u00a0Opin\u00a0Pulm\u00a0Med"},{"key":"10.1016\/j.coi.2025.102673_bib11","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jdcr.2023.04.015","article-title":"Sarcoidal granulomatous reaction to microneedling with vitamin C serum","volume":"36","author":"Handal","year":"2023","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.coi.2025.102673_bib12","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1007\/s10067-021-05684-w","article-title":"Whole genome sequencing identifies variants associated with sarcoidosis in a family with a high prevalence of sarcoidosis","volume":"40","author":"Fritz","year":"2021","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.coi.2025.102673_bib13","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s40257-022-00693-0","article-title":"The evolving landscape of cutaneous sarcoidosis: pathogenic insight, clinical challenges, and new frontiers in therapy","volume":"23","author":"Wu","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.coi.2025.102673_bib14","series-title":"Sarcoidosis: A Clinician\u2019s Guide","first-page":"127","article-title":"Cutaneous sarcoidosis","author":"Imadojemu","year":"2018"},{"key":"10.1016\/j.coi.2025.102673_bib15","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1056\/NEJMoa1805958","article-title":"Tofacitinib treatment and molecular analysis of cutaneous sarcoidosis","volume":"379","author":"Damsky","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2025.102673_bib16","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.jaad.2019.05.098","article-title":"Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare","volume":"82","author":"Damsky","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coi.2025.102673_bib17","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.030478","article-title":"An mTORC1-dependent mouse model for cardiac sarcoidosis","volume":"12","author":"Bueno-Beti","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.coi.2025.102673_bib18","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02695-2020","article-title":"Phagosome-regulated mTOR signalling during sarcoidosis granuloma biogenesis","volume":"57","author":"Crouser","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.coi.2025.102673_sbref19","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/ni.3655","article-title":"Chronic signaling via the metabolic checkpoint kinase mTORC1 induces macrophage granuloma formation and marks sarcoidosis progression","volume":"18","author":"Linke","year":"2017","journal-title":"Nat Immunol"},{"key":"10.1016\/j.coi.2025.102673_bib20","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02950-2020","article-title":"Transcriptomics of bronchoalveolar lavage cells identifies new molecular endotypes of sarcoidosis","volume":"58","author":"Vukmirovic","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.coi.2025.102673_bib21","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1016\/S2665-9913(23)00302-8","article-title":"Efficacy and safety of mTOR inhibition in cutaneous sarcoidosis: a single-centre trial","volume":"6","author":"Redl","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.coi.2025.102673_sbref22","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1161\/CIRCRESAHA.121.320449","article-title":"Transcriptional and immune landscape of cardiac sarcoidosis","volume":"131","author":"Liu","year":"2022","journal-title":"Circ Res"},{"key":"10.1016\/j.coi.2025.102673_bib23","first-page":"6","article-title":"How many organs need to be involved to diagnose sarcoidosis?: An unanswered question that, hopefully, will become irrelevant","volume":"31","author":"Judson","year":"2014","journal-title":"Sarcoidosis Vasc Diffuse\u00a0Lung Dis"},{"key":"10.1016\/j.coi.2025.102673_bib24","first-page":"1725","article-title":"Isolated cutaneous sarcoidosis: a new insight into the old entity","volume":"7","author":"Sharath Kumar","year":"2013","journal-title":"J Clin Diagn Res"},{"key":"10.1016\/j.coi.2025.102673_bib25","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4103\/0976-9668.95980","article-title":"Isolated facial cutaneous sarcoidosis","volume":"3","author":"Kumar","year":"2012","journal-title":"J Nat Sci Biol Med"},{"key":"10.1016\/j.coi.2025.102673_bib26","doi-asserted-by":"crossref","first-page":"699.e1","DOI":"10.1016\/j.jaad.2011.11.965","article-title":"Sarcoidosis: a comprehensive review and update for the dermatologist: part I. Cutaneous disease","volume":"66","author":"Haimovic","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coi.2025.102673_bib27","doi-asserted-by":"crossref","DOI":"10.1186\/1752-1947-8-17","article-title":"High rate of cardiac sarcoidosis presenting with cutaneous plaque type sarcoidosis in 18F-fluorodeoxyglucose positron emission tomography-computed tomography: a case series","volume":"8","author":"Nakamura","year":"2014","journal-title":"J Med Case Rep"},{"key":"10.1016\/j.coi.2025.102673_bib28","doi-asserted-by":"crossref","first-page":"699.e1","DOI":"10.1016\/j.jaad.2011.11.965","article-title":"Sarcoidosis: a comprehensive review and update for the dermatologist: Part I. Cutaneous disease","volume":"66","author":"Haimovic","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coi.2025.102673_sbref29","article-title":"Clinicopathologic features, demographics, disease burden, and therapeutics in alopecic sarcoidosis: a case series and systematic review","volume":"10","author":"Obijiofor","year":"2024","journal-title":"Int J Womens Dermatol"},{"key":"10.1016\/j.coi.2025.102673_bib30","doi-asserted-by":"crossref","DOI":"10.1001\/jamadermatol.2022.3255","article-title":"Nail sarcoidosis","volume":"158","author":"Ward","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.coi.2025.102673_bib31","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s11926-022-01089-z","article-title":"Neurosarcoidosis: phenotypes, approach to diagnosis and treatment","volume":"24","author":"Gosselin","year":"2022","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.coi.2025.102673_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2022.577864","article-title":"Peripheral neuropathy in sarcoidosis","volume":"368","author":"Tavee","year":"2022","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.coi.2025.102673_bib33","first-page":"427","article-title":"Foreign bodies in granulomatous cutaneous lesions of patients with systemic sarcoidosis","volume":"137","author":"Marcoval","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.coi.2025.102673_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jdcr.2020.12.021","article-title":"Treatment of cutaneous sarcoidosis with tofacitinib 2% ointment and extra virgin olive oil","volume":"9","author":"Alam","year":"2021","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.coi.2025.102673_bib35","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jdcr.2020.11.016","article-title":"Treatment of angiolupoid sarcoidosis with tofacitinib ointment 2% and pulsed dye laser therapy","volume":"7","author":"Singh","year":"2020","journal-title":"JAAD Case Rep]"},{"key":"10.1016\/j.coi.2025.102673_bib36","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1001\/jamadermatol.2013.2977","article-title":"Oral minocycline in treatment of cutaneous sarcoidosis","volume":"149","author":"Steen","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.coi.2025.102673_bib37","article-title":"Hydroxychloroquine monotherapy in sarcoidosis: indications, efficacy, and side effects","volume":"41","author":"Vermeer","year":"2024","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.coi.2025.102673_bib38","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1684\/ejd.2023.4584","article-title":"Which first-line treatment for cutaneous sarcoidosis? A retrospective study of 120 patients","volume":"33","author":"Cohen","year":"2023","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.coi.2025.102673_bib39","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1001\/archdermatol.2011.301","article-title":"Efficacy and safety of apremilast in chronic cutaneous sarcoidosis","volume":"148","author":"Baughman","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.coi.2025.102673_bib40","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/jama.2022.1570","article-title":"Diagnosis and treatment of pulmonary sarcoidosis: a review","volume":"327","author":"Belperio","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.coi.2025.102673_bib41","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.jaad.2011.06.017","article-title":"Molecular profiling and gene expression analysis in cutaneous sarcoidosis: the role of interleukin-12, interleukin-23, and the T-helper 17 pathway","volume":"66","author":"Judson MA","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coi.2025.102673_bib42","first-page":"289","article-title":"Infliximab for chronic cutaneous sarcoidosis: a subset analysis from a double-blind randomized clinical trial","volume":"32","author":"Baughman","year":"2016","journal-title":"Sarcoidosis Vasc Diffuse\u00a0Lung Dis"},{"key":"10.1016\/j.coi.2025.102673_bib43","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1378\/chest.08-1347","article-title":"The treatment of lupus pernio: results of 116 treatment courses in 54 patients","volume":"135","author":"Stagaki","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.coi.2025.102673_bib44","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1378\/chest.124.1.177","article-title":"Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis","volume":"124","author":"Utz","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.coi.2025.102673_bib45","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S0012-3692(15)50471-6","article-title":"Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial","volume":"128","author":"Baughman","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.coi.2025.102673_bib46","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01482-2018","article-title":"Dramatic response of refractory sarcoidosis under ruxolitinib in a patient with associated JAK2-mutated polycythemia","volume":"52","author":"Rotenberg","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.coi.2025.102673_bib47","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jdcr.2019.02.006","article-title":"Resolution of cutaneous sarcoidosis after Janus kinase inhibitor therapy for concomitant polycythemia vera","volume":"5","author":"Wei","year":"2019","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.coi.2025.102673_bib48","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jdcr.2021.08.012","article-title":"Treatment of cutaneous sarcoidosis with tofacitinib: a case report and review of evidence for Janus kinase inhibition in sarcoidosis","volume":"16","author":"Talty","year":"2021","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.coi.2025.102673_bib49","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ejim.2021.12.016","article-title":"Glucocorticoid sparing in sarcoidosis using the Janus kinase (JAK) inhibitor tofacitinib","volume":"98","author":"Belliere","year":"2022","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.coi.2025.102673_bib50","doi-asserted-by":"crossref","DOI":"10.1186\/s12969-021-00634-x","article-title":"Tofacitinib effectiveness in Blau syndrome: a case series of Chinese paediatric patients","volume":"19","author":"Zhang","year":"2021","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.coi.2025.102673_bib51","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/acr2.11112","article-title":"Treatment of multiorgan sarcoidosis with tofacitinib","volume":"2","author":"Damsky","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.coi.2025.102673_sbref52","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-30615-x","article-title":"Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis","volume":"13","author":"Damsky","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.coi.2025.102673_bib53","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jdcr.2023.06.006","article-title":"Management of treatment-resistant angiolupoid sarcoidosis with adalimumab and tofacitinib 2% ointment","volume":"38","author":"Costanza","year":"2023","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.coi.2025.102673_bib54","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00408-021-00436-8","article-title":"Tofacitinib as a steroid-sparing therapy in pulmonary sarcoidosis, an open-label prospective proof-of-concept study","volume":"199","author":"Friedman","year":"2021","journal-title":"Lung"},{"key":"10.1016\/j.coi.2025.102673_bib55","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1136\/annrheumdis-2020-217271","article-title":"Steroid-resistant sarcoidosis treated with baricitinib","volume":"79","author":"Scheinberg","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102673_bib56","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1136\/annrheumdis-2019-215387","article-title":"Refractory sarcoidosis-like systemic granulomatosis responding to ruxolitinib","volume":"78","author":"Levraut","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102673_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.152102","article-title":"Sarcoidosis incidence after mTOR inhibitor treatment","volume":"57","author":"Baker","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.coi.2025.102673_bib58","doi-asserted-by":"crossref","DOI":"10.1080\/25310429.2024.2422210","article-title":"Complete response to mTOR inhibitor following JAKi failure in severe pulmonary sarcoidosis","volume":"31","author":"Hindr\u00e9","year":"2025","journal-title":"Pulmonology"},{"key":"10.1016\/j.coi.2025.102673_bib59","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2020-235372","article-title":"Treatment-recalcitrant laryngeal sarcoidosis responsive to sirolimus","volume":"13","author":"Kelleher","year":"2020","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.coi.2025.102673_bib60","doi-asserted-by":"crossref","first-page":"E119","DOI":"10.1164\/rccm.202004-0914IM","article-title":"Successful response to treatment with sirolimus in pulmonary sarcoidosis","volume":"202","author":"Gupta","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.coi.2025.102673_sbref61","doi-asserted-by":"crossref","first-page":"00536","DOI":"10.1183\/23120541.00536-2024","article-title":"Therapeutic doses of efzofitimod demonstrate efficacy in pulmonary sarcoidosis","volume":"11","author":"Obi","year":"2025","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.coi.2025.102673_bib62","article-title":"Tocilizumab in sarcoidosis patients failing steroid sparing therapies and anti-TNF agents","volume":"1","author":"Sharp","year":"2019","journal-title":"Respir Med X [Internet]"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791525001499?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791525001499?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T08:40:15Z","timestamp":1775032815000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791525001499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":62,"alternative-id":["S0952791525001499"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2025.102673","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"When granulomatous inflammation becomes visible: insights into cutaneous sarcoidosis","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2025.102673","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102673"}}